Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
April 26, 2018
Cobra Biologics

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products.

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products.

-
Cobra Biologics
-
April 26, 2018

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products.

Keele (UK), 21 April 2018: Cobra Biologics a leading international contract development and manufacturing organisation (CDMO), today announced that it has been awarded the Queen’s Award 2018 for Enterprise, in the International Trade category. The prestigious award is in recognition of Cobra’s commercial success in providing services to its global customer base.

Now in their 53rd year, the Queen’s Awards have a long history of recognising exceptional UK businesses and Cobra will be attending a reception at Buckingham Palace followed by a presentation of the Award by a representative of Her Majesty The Queen at Cobra’s UK facility later in the year.

Cobra has a 20 year track record of supporting the life science industry with contract development and manufacturing of biopharmaceuticals, from preclinical through to clinical trials and commercial supply and currently exports over 85% of its services from its facilities based in the UK and Sweden.

Cobra’s UK based GMP approved facility is a globally recognised centre of excellence for the development and production of biological material to support both gene- and immuno-therapy. In April 2017, Cobra announced a £15 million gene therapy expansion plan, to meet the increased demand from both plasmid DNA and viral vectors for Phase III and Commercial supply to support both existing and new customer requirements in the development of revolutionary disease therapies.

Peter Coleman, Chief Executive of Cobra Biologics, commented: “

I am immensely proud of what Cobra has achieved over the last few years, culminating in the Queen’s Award. International Trade is vitally important for Cobra and the work that we do is challenging and requires a committed work force whose skills and dedication attract business from all over the world. I would like also to thank the Office for Life Science, Innovate UK and the Department for International Trade for their support of our expansion plans in the UK.”  

Media Coverage:

BioNow

BioPortfolio

Birmingham Post

Business Wire

Business Wire Sweden

Department for Business, Energy & Industrial Strategy

FinanzNachrichten

Innovate UK

Insider Media

Läkemedelsmarknaden

Manufacturing Chemist

News Observatory

Nordic Life Science News

Staffordshire Newsroom

Technology Networks

The Business Desk

The London Gazette

The Manufacturer

The Sentinel

US & World News

Yahoo Finance

Zyme Communications

4-Traders

Last updated:
April 26, 2018

Cobra Biologics

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products.

Keele (UK), 21 April 2018: Cobra Biologics a leading international contract development and manufacturing organisation (CDMO), today announced that it has been awarded the Queen’s Award 2018 for Enterprise, in the International Trade category. The prestigious award is in recognition of Cobra’s commercial success in providing services to its global customer base.

Now in their 53rd year, the Queen’s Awards have a long history of recognising exceptional UK businesses and Cobra will be attending a reception at Buckingham Palace followed by a presentation of the Award by a representative of Her Majesty The Queen at Cobra’s UK facility later in the year.

Cobra has a 20 year track record of supporting the life science industry with contract development and manufacturing of biopharmaceuticals, from preclinical through to clinical trials and commercial supply and currently exports over 85% of its services from its facilities based in the UK and Sweden.

Cobra’s UK based GMP approved facility is a globally recognised centre of excellence for the development and production of biological material to support both gene- and immuno-therapy. In April 2017, Cobra announced a £15 million gene therapy expansion plan, to meet the increased demand from both plasmid DNA and viral vectors for Phase III and Commercial supply to support both existing and new customer requirements in the development of revolutionary disease therapies.

Peter Coleman, Chief Executive of Cobra Biologics, commented: “

I am immensely proud of what Cobra has achieved over the last few years, culminating in the Queen’s Award. International Trade is vitally important for Cobra and the work that we do is challenging and requires a committed work force whose skills and dedication attract business from all over the world. I would like also to thank the Office for Life Science, Innovate UK and the Department for International Trade for their support of our expansion plans in the UK.”  

Media Coverage:

BioNow

BioPortfolio

Birmingham Post

Business Wire

Business Wire Sweden

Department for Business, Energy & Industrial Strategy

FinanzNachrichten

Innovate UK

Insider Media

Läkemedelsmarknaden

Manufacturing Chemist

News Observatory

Nordic Life Science News

Staffordshire Newsroom

Technology Networks

The Business Desk

The London Gazette

The Manufacturer

The Sentinel

US & World News

Yahoo Finance

Zyme Communications

4-Traders

Last updated:
April 26, 2018

Cobra Biologics

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail